Linda Cingolani

Statistics

Publications

Citations

112

H-Index

Active since

2020

Affiliations

University of Padua(Current)

University of Genoa

University of Pisa

Ospedale Policlinico San Martino

Linda Cingolani is an author at University of Padua specializing in inflammatory bowel disease, biosimilar use, and inflammatory disease pharmacotherapy.

ORCID

Publications per year

2020–2023

Publications

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Linda Cingolani, Brigida Barberio, Fabiana Zingone et al. · Scientific Reports · 2021 · 37 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study

Fabiana Zingone, Monica Siniscalchi, Edoardo Savarino et al. · Journal of Medical Internet Research · 2020 · 22 citations · Full text

Medicine, Health Sciences, Clinical Epidemiology +5

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

Brigida Barberio, Linda Cingolani, Cristina Canova et al. · Therapeutic Advances in Gastroenterology · 2021 · 20 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

Davide Massimi, Brigida Barberio, Lorenzo Bertani et al. · Therapeutic Advances in Gastroenterology · 2021 · 12 citations · Full text

Pharmacy, Immunology, Pharmacology +17

Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study

Antonio Tursi, Giammarco Mocci, Linda Cingolani et al. · Expert Opinion on Pharmacotherapy · 2023 · 11 citations

Medicine, Clinical Sciences, Pharmacotherapy +13

1–5 of 6